Shortage of Valproate Sodium Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA has listed Valproate Sodium Injection as currently in shortage, affecting its availability for neurology treatments, with one manufacturer reporting it as available but with caveats.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 8, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Valproate Sodium Injection.
What's in Shortage
The drug in shortage is Valproate Sodium Injection, with brand name VALPROATE SODIUM. It is available in injection dosage form and is categorized under neurology. The shortage status is current, first posted on 12/30/2020 and last updated on 04/02/2026.
Which Manufacturers Are Affected
Fresenius Kabi USA, LLC is the manufacturer affected. Their availability status is available, with a note to check wholesalers for inventory. The presentation is Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05). Contact information is 888-386-1300.
Why There's a Shortage
No specific reason for the shortage was provided in the source data.
What Patients Should Do
Patients should talk to their pharmacist about the current availability of Valproate Sodium Injection and ask about general options. They can also contact the manufacturer directly using the provided information. Remember, patients should consult their healthcare provider for any medical advice and not make changes without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,112 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 8, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.